ASIA BEAT: Japan gets feel-good, Taiwan makes NICE
This article was originally published in Scrip
As Japan's pharma majors prepare to announce results generally in line with guidance for the nine months ended 31 December, investors' eyes are turning more to upside factors for the final quarter of the fiscal year on the back of new government policies.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.